Purified anti-mouse Ly-6G/Ly-6C (Gr-1) Antibody

Pricing & Availability
Clone
RB6-8C5 (See other available formats)
Regulatory Status
RUO
Other Names
Gr-1
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
RB6-8C5_Pure_040912
C57BL/6 mouse bone marrow cells were stained with purified Ly-6G/Ly-6C (clone RB6-8C5) (filled histogram) or rat IgG2b, κ isotype control (open histogram), followed by anti-rat IgG FITC. Data shown was gated on myeloid cell population.
  • RB6-8C5_Pure_040912
    C57BL/6 mouse bone marrow cells were stained with purified Ly-6G/Ly-6C (clone RB6-8C5) (filled histogram) or rat IgG2b, κ isotype control (open histogram), followed by anti-rat IgG FITC. Data shown was gated on myeloid cell population.
Compare all formats
Cat # Size Price Save
108401 50 µg ¥4,620
108402 500 µg ¥20,790
Description

Gr-1 is a 21-25 kD protein also known as Ly-6G/Ly-6C. This myeloid differentiation antigen is a glycosylphosphatidylinositol (GPI)-linked protein expressed on granulocytes and macrophages. In bone marrow, the expression levels of Gr-1 directly correlate with granulocyte differentiation and maturation; Gr-1 is also transiently expressed on bone marrow cells in the monocyte lineage. Immature Myeloid Gr-1+ cells play a role in the development of antitumor immunity.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Raised against granulocytes of mouse origin
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography.
Concentration
0.5 mg/ml
Storage & Handling
The Ly-6G/Ly-6C antibody solution should be stored undiluted between 2°C and 8°C.
Application

FC - Quality tested
IP, IHC, WB - Reported in the literature, not verified in house

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.06 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

Clone RB6-8C5 binds with high affinity to mouse Ly-6G molecules and to a lower extent to Ly-6C19. Clone RB6-8C5 impairs the binding of anti-mouse Ly-6G clone 1A819. However, clone RB6-8C5 is able to stain in the presence of anti-mouse Ly-6C clone HK1.420.

The RB6-8C5 antibody has been used to identify peripheral blood neutrophils and deplete granulocytes in vivo. Additional reported applications (for relevant formats of this clone) include: in vitro complement-mediated cytotoxicity2, in vivo depletion3-5,9, immunoprecipitation1, immunohistochemical staining6 (including paraffin-embedded sections9,16,33-35, acetone-fixed frozen sections11 and zinc-fixed sections15), and Western blotting7. RB6-8C5 is not suitable for depletion of hepatic myeloid derived suppressor cells (MDSCs)20.

Special Note: For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 108436).

Application References

(PubMed link indicates BioLegend citation)
  1. Fleming TJ, et al. 1993. J. Immunol. 151:2399. (IP)
  2. Brummer E, et al. 1984. J. Leukocyte Biol. 36:505. (CMCD)
  3. Stoppacciaro A, et al. 1993. J. Exp. Med. 178:151. (Deplete)
  4. Tumpey TM, et al. 1996. J. Virol. 70:898. (Deplete)
  5. Czuprynski CJ, et al. 1994. J. Immunol. 152:1836. (Deplete)
  6. Nitta H, et al. 1997. Cell Vision 4:73. (IHC)
  7. Jutila MA, et al. 1988. Eur. J. Immunol. 18:1819. (WB)
  8. Engwerda CR, et al. 2004. Am. J. Pathol. 165:2123.
  9. Brown CR, et al. 2004. Infect. Immun. 72:4956. (Deplete, IHC)
  10. Andoniou CE, et al. 2005. Nature Immunology 6:1011. (FC) PubMed
  11. Li M, et al. 2006. P. Natl. Acad. Sci USA 103:11736. (IHC)
  12. Dzhagalov I, et al. 2007. Blood 109:1620. (FC) PubMed
  13. Fazilleau N, et al. 2007. Nature Immunol. 8:753. (FC) PubMed
  14. Heuser M, et al. 2007. Blood 110:1639. (FC) PubMed
  15. Wang T, et al. 2007. Infect. Immun. 75:1144. (IHC)
  16. Bosio CM, et al. 2007. J. Immunol. 178:4538. (IHC)
  17. Boehme SA, et al. 2009. Int. Immunol. 21:81. (IHC)
  18. Piao Y, et al. 2012. Neuro Oncol. 14:1379. PubMed
  19. Ribechini E, et al. 2009. Eur. J. Immunol. 39:3538.
  20. Ma C, et al. 2012. J. Leukoc. Biol. 92:1199.
  21. Li J, et al. 2012. Arthritis Rheum. 64:1098. PubMed
  22. Fan Q, et al. 2014. Cancer Res. 74:471. PubMed
  23. Korrer MJ, et al. 2014. PLoS One. 9:91370. PubMed
  24. Morshed M, et al. 2014. J Immunol. 192:5314. PubMed
  25. Collins C, et al. 2014. PNAS. 111:9899. PubMed
  26. Madireddi S, et al. 2014. J Exp Med. 211:1433. PubMed
  27. Bianchi G, et al. 2014. Cell Death Dis. 5:1135. PubMed
  28. Guo H, et al. 2014. J Leukoc Biol. 96:419. PubMed
  29. Roderick JE, et al. 2014. PNAS. 111:14436. PubMed
  30. Distel E, et al. 2014. Circ Res. 115:759. PubMed
  31. Iwai H, et al. 2015. Tuberculosis. 95:246. PubMed
  32. Charmsaz S, et al. 2015. PLoS One. 10:130692. PubMed
  33. Whiteland J, et al. 1994 J Histochem Cytochem 43:3 (IHC-P)
  34. Brown C, et al. 2003 J Immunology 171:2 (IHC-P)
  35. Obregon-Henao A, et al. PLoS One 8:11 (IHC-P)
Product Citations
  1. Wolf Y, et al. 2017. J Exp Med. 214:905. PubMed
  2. Ramirez-Moral I, et al. 2021. J Pathol. 253:374. PubMed
  3. Matsuno Y, et al. 2007. Am J Respir Crit Care Med. 176:1015. PubMed
  4. Weidner H, et al. 2020. JCI Insight. 5:00. PubMed
  5. Li Y, et al. 2022. Int J Biol Sci. 18:3697. PubMed
  6. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
  7. Bachran C, et al. 2017. Sci Rep.. 10.1038/s41598-017-17948-0. PubMed
  8. Nederhoff MGJ, et al. 2019. Auton Neurosci. 221:102580. PubMed
  9. Wang W, et al. 2018. Cancer Cell. 34:757. PubMed
  10. Arnold IC, et al. 2018. J Exp Med. 215:2055. PubMed
  11. Zou C, et al. 2020. Cell Rep. 33:108447. PubMed
  12. Yang J, et al. 2022. Biosci Rep. :. PubMed
  13. Hameed AM, et al. 2020. Sci Rep. 5.229166667. PubMed
  14. Cao Q, et al. 2018. Am J Physiol Renal Physiol. 314:F561. PubMed
  15. Periasamy S, et al. 2017. Nat Commun. 8:15564. PubMed
  16. Nguyen N, et al. 2022. iScience. 25:103679. PubMed
  17. Zalacain M, et al. 2021. Mol Ther Oncolytics. 20:23. PubMed
  18. Ronkina N, et al. 2019. J Immunol. 203:2291. PubMed
  19. Dave K et al. 2017. eLife. 6 pii: e23382. PubMed
  20. Bernal S, et al. 2020. British Journal of Pharmacology. 178(3):564-581. PubMed
  21. Lopez-Sanz L, et al. 2021. Clinical and Translational Medicine. 11(7):e463. PubMed
  22. Joseph R, et al. 2021. Br J Cancer. 125:176. PubMed
  23. Gautam J, et al. 2020. J Neuroinflammation. 17:103. PubMed
  24. McCormick B, et al. 2019. J Immunol. 203:1579. PubMed
  25. Magod P, et al. 2021. Cell Reports. 36(5):109480. PubMed
  26. Peng V, et al. 2020. J Biol Chem. 295:14866. PubMed
  27. Yang M, et al. 2020. Oncoimmunology. 9:1708064. PubMed
  28. Liu Y, et al. 2022. Nat Commun. 13:2665. PubMed
  29. Pérez-Hernández M, et al. 2021. Front Physiol. 11:623190. PubMed
  30. Hawila E, et al. 2017. Cell Rep.. 10.1016/j.celrep.2017.10.104. PubMed
  31. Chen S, et al. 2018. Immunohorizons. 0.345138889. PubMed
  32. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
  33. Suzuki Y, et al. 2021. FEBS Open Bio. 11:2619. PubMed
  34. Wang H, et al. 2021. Nat Commun. 12:4826. PubMed
  35. Yang SH, et al. 2017. Front Immunol. 8:1192. PubMed
  36. Zhao L, et al. 2018. Nat Med. 24:1536. PubMed
  37. Chen X et al. 2017. Cell stem cell. 21(6):747-760 . PubMed
  38. Sun Y, et al. 2022. Nat Commun. 13:3916. PubMed
  39. Telford W, et al. 2017. Cytometry A. 91:314. PubMed
  40. Mainini F, et al. 2018. Nucleic Acid Ther. 28:225. PubMed
  41. Mori H, et al. 2015. Toxicol Pathol. 43: 883-889. PubMed
  42. Arnold S, et al. 2008. Exp Biol Med. 233:860. PubMed
  43. Umemoto T, et al. 2017. EMBO J. 36:2390. PubMed
  44. Tsubaki T, et al. 2018. Oncotarget. 9:11209. PubMed
  45. Wicki S, et al. 2018. Int J Mol Sci. 1.266666667. PubMed
  46. Hu G, et al. 2021. Nat Commun. 12:773. PubMed
  47. Enders M, et al. 2020. J Immunol. 204:87. PubMed
  48. Godoy-Calderón MJ, et al. 2018. Oncotarget. 8:11370. PubMed
  49. Piao Y, et al. 2012. Neuro Oncology. 14:1379. PubMed
  50. Artz A, Butz S, Vestweber D 2016. Am J Physiol Renal Physiol. 311: F176 - F181. PubMed
  51. Schuler CF, et al. 2020. Allergy. 75:2279. PubMed
  52. Shevchenko MA, et al. 2018. J Immunol Res. 8:53. PubMed
  53. Parigi SM, et al. 2018. Sci Rep. 0.440277778. PubMed
  54. Ford J, et al. 2019. Front Immunol. 2.502083333. PubMed
  55. Wang SS, et al. 2021. Cell Chemical Biology. 28(5):699-710.e5. PubMed
  56. Wu Y, et al. 2020. Biol Reprod. 1213:102. PubMed
  57. Tsukui H, et al. 2020. BMC Cancer. 20:411. PubMed
  58. Zhang P, et al. 2022. Nat Commun. 13:1588. PubMed
  59. Ritchie N, Ijaz U, and Evans T. 2017. BMC Genomics.. 10.1186/s12864-017-4215-3. PubMed
  60. Nguyen CH, et al. 2020. Biomedicines. 8:. PubMed
  61. Bogorodskiy AO, et al. 2020. Front Immunol. 11:298. PubMed
  62. Akiel M, et al. 2017. Cancer Res. 77:4014. PubMed
  63. Ren AQ, et al. 2021. Front Pharmacol. 12:693298. PubMed
  64. Ruiz-Fernandez de Cordoba B, et al. 2022. Cancer Discov. . PubMed
  65. Scortegagna M, et al. 2020. Nat Commun. 11:99. PubMed
  66. Link CWM, et al. 2020. Front Immunol. 11:596772. PubMed
  67. Lin Z, et al. 2021. Stem Cells. 39:240. PubMed
  68. Hwang BJ, et al. 2019. Oncogene. 38:7491. PubMed
  69. Lee YJ, et al. 2018. Front Microbiol. 9:83. PubMed
  70. Satoh–Takayama N, et al. 2020. Immunity. 52(4):635-649. PubMed
  71. Mohrin M, et al. 2021. Aging Cell. 20:e13313. PubMed
  72. Cané S, et al. 2021. J Immunother Cancer. 9:. PubMed
  73. Jin H, et al. 2021. Int J Mol Sci. 22:. PubMed
  74. Diao J, et al. 2018. J Immunol. 201:1306. PubMed
  75. Pushalkar S, et al. 2018. Cancer Discov. 0.613194444. PubMed
  76. Winter C, et al. 2018. Cell Metab. 28:175. PubMed
  77. Heib T, et al. 2021. Cell Reports. 35(6):109102. PubMed
  78. Rios–Doria J, et al. 2017. Cancer Res. 77:2686. PubMed
  79. Zhang J, et al. 2019. Onco Targets Ther. 12:4985. PubMed
  80. Song M, et al. 2020. Nat Commun. 11:6298. PubMed
  81. Dubik M, et al. 2021. Front Neurosci. 15:682451. PubMed
  82. Shao Y, et al. 2017. Onco Targets Ther. 10:2675. PubMed
  83. He X, et al. 2017. Cancer Biol Ther. 0.815277778. PubMed
  84. Sparber F et al. 2019. British journal of pharmacology. 176(11):1728-1744 . PubMed
  85. Alrefai H, et al. 2016. Nat Commun. 7:11724. PubMed
RRID
AB_313366 (BioLegend Cat. No. 108401)
AB_313367 (BioLegend Cat. No. 108402)

Antigen Details

Structure
21-25 kD
Distribution

Granulocytes, monocytes

Cell Type
Granulocytes, Monocytes, Neutrophils
Biology Area
Immunology, Innate Immunity
Antigen References

1. Fleming TJ, et al. 1993. J. Immunol. 151:2399.
2. Jutila MA, et al. 1988. Eur. J. Immunol. 18:1819.
3. Goni O, et al. 2002. Int. Immunol. 14:1125.

Gene ID
17067 View all products for this Gene ID 546644 View all products for this Gene ID
UniProt
View information about Ly-6G Ly-6C on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All Ly-6G/Ly-6C Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Biotin anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC, IHC, IP, WB
FITC anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
PE anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
PE/Cyanine5 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Purified anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC, IHC, IP, WB
PE/Cyanine7 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Alexa Fluor® 488 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC, IHC
Alexa Fluor® 647 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Alexa Fluor® 700 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Brilliant Violet 711™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
APC/Cyanine7 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Pacific Blue™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
PerCP/Cyanine5.5 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
PerCP anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Brilliant Violet 421™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Brilliant Violet 570™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Ultra-LEAF™ Purified anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC, IP, CMCD, Depletion, IHC, WB
Brilliant Violet 510™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Brilliant Violet 605™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Brilliant Violet 650™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Alexa Fluor® 594 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 IHC-F, FC
Purified anti-mouse Ly-6G/Ly-6C (Gr-1) (Maxpar® Ready) RB6-8C5 FC, CyTOF®
PE/Dazzle™ 594 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
APC/Fire™ 750 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
TotalSeq™-A0116 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 PG
TotalSeq™-C0116 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 PG
TotalSeq™-B0116 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 PG
Spark Blue™ 550 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
APC/Fire™ 810 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Spark Violet™ 423 anti-mouse Ly-6G/Ly-6C (GR-1) Antibody RB6-8C5 FC
Spark UV™ 387 anti-mouse Ly-6G/Ly-6C (GR-1) RB6-8C5 FC
Go To Top Version: 3    Revision Date: 11/19/2019

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

 

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

 

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

  • APC anti-mouse Ly-6G/Ly-6C (Gr-1)

  • Biotin anti-mouse Ly-6G/Ly-6C (Gr-1)

  • FITC anti-mouse Ly-6G/Ly-6C (Gr-1)

  • PE anti-mouse Ly-6G/Ly-6C (Gr-1)

  • PE/Cyanine5 anti-mouse Ly-6G/Ly-6C (Gr-1)

  • Purified anti-mouse Ly-6G/Ly-6C (Gr-1)

  • PE/Cyanine7 anti-mouse Ly-6G/Ly-6C (Gr-1)

  • Alexa Fluor® 488 anti-mouse Ly-6G/Ly-6C (Gr-1)

  • Alexa Fluor® 647 anti-mouse Ly-6G/Ly-6C (Gr-1)

  • Alexa Fluor® 700 anti-mouse Ly-6G/Ly-6C (Gr-1)

  • Brilliant Violet 711™ anti-mouse Ly-6G/Ly-6C (Gr-1)

  • APC/Cyanine7 anti-mouse Ly-6G/Ly-6C (Gr-1)

  • Pacific Blue™ anti-mouse Ly-6G/Ly-6C (Gr-1)

  • PerCP/Cyanine5.5 anti-mouse Ly-6G/Ly-6C (Gr-1)

  • PerCP anti-mouse Ly-6G/Ly-6C (Gr-1)

  • Brilliant Violet 421™ anti-mouse Ly-6G/Ly-6C (Gr-1)

  • Brilliant Violet 570™ anti-mouse Ly-6G/Ly-6C (Gr-1)

  • Ultra-LEAF™ Purified anti-mouse Ly-6G/Ly-6C (Gr-1)

  • Brilliant Violet 510™ anti-mouse Ly-6G/Ly-6C (Gr-1)

  • Brilliant Violet 605™ anti-mouse Ly-6G/Ly-6C (Gr-1)

  • Brilliant Violet 650™ anti-mouse Ly-6G/Ly-6C (Gr-1)

  • Alexa Fluor® 594 anti-mouse Ly-6G/Ly-6C (Gr-1)

  • Purified anti-mouse Ly-6G/Ly-6C (Gr-1) (Maxpar® Ready)

  • PE/Dazzle™ 594 anti-mouse Ly-6G/Ly-6C (Gr-1)

  • APC/Fire™ 750 anti-mouse Ly-6G/Ly-6C (Gr-1)

  • TotalSeq™-A0116 anti-mouse Ly-6G/Ly-6C (Gr-1)

  • TotalSeq™-C0116 anti-mouse Ly-6G/Ly-6C (Gr-1)

  • TotalSeq™-B0116 anti-mouse Ly-6G/Ly-6C (Gr-1)

  • Spark Blue™ 550 anti-mouse Ly-6G/Ly-6C (Gr-1)

  • APC/Fire™ 810 anti-mouse Ly-6G/Ly-6C (Gr-1)

  • Spark Violet™ 423 anti-mouse Ly-6G/Ly-6C (GR-1) Antibody

  • Spark UV™ 387 anti-mouse Ly-6G/Ly-6C (GR-1)

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account